BCR and B-cell chronic lymphocytic leukemia: Treatment of CLL cells in vitro by inhibitors of BCR-signaling and MYC blocked the anti-IgM-induced changes, and CLL cells from patients on ibrutinib showed strong reduction in basal levels of hexokinase 2 (HK2) with treatment.